67.8% of CagriSema recipients lost 5% of their weight by week eight
Key Facts
Novo Nordisk announced results on November 15 from two post hoc analyses of the REDEFINE 1 trial, which were presented at ObesityWeek 2026 in Washington. The data showed that 67.8% of adults who received CagriSema at a dose of 2.4/2.4 mg had lost at least 5% of their weight by week eight. The company described these participants as early responders to treatment. In a post hoc exploratory analysis, the observed mean weight loss in this group was 25.4% at week 68. The results also highlighted differences in treatment outcomes based on response timing, as well as improved physical function in a proportion of participants.
The observed mean weight loss at week 68 was about 17.8% among those who responded to treatment later, compared with 25.4% among early responders. The 25.4% figure applies to the early responder group and does not represent the mean weight loss of all trial participants. In a separate analysis, 73.1% of those who received CagriSema reported a meaningful improvement in physical function at week 68. The corresponding share in the placebo group was 49.1%. These results measure the share of participants who reported improved physical function, alongside changes in weight over the trial period.
Efficacy measures were accompanied by a signal on discontinuation due to side effects: REDEFINE 1 recorded discontinuation among 5.9% of CagriSema recipients, compared with 3.5% of the placebo group. The side effects prompting discontinuation were mostly gastrointestinal, according to the company. These rates provide one aspect of the treatment’s tolerability profile alongside the weight-loss and physical-function results. The early-response analysis remains a post hoc exploratory analysis, as described in the published data. Its results are presented in the context of a clinical trial, not as a guarantee of a similar outcome for every patient.
In the real-world SIGNAL study, follow-up included 26,213 adults who had not previously received treatment, and the adjusted mean food-noise score fell by 0.42 points during the first month. The decline continued through month six, when it reached 0.72 points from baseline. The study examined food noise, a term for an intense or recurring desire to eat, in data on patients’ treatment experiences. The company also presented results from the OCTANE study, in which oral semaglutide use was associated with an approximately 25% decline in mean reported food-noise scores over three months. In OCTANE, 86.4% of participants said they had noticed at least one treatment benefit.
The SIGNAL and OCTANE studies were based on two retrospective analyses of de-identified patient data from the Ro platform and used a validated seven-question survey to measure food noise. Novo said real-world studies observe associations and do not establish causation. It also noted that results could be affected by bias in data reported by participants themselves or by selection bias. This limitation frames the food-noise findings as patient-reported experiences, without establishing that treatment alone caused the recorded change. Before the conference, the company said its presentation program would also cover Wegovy use among adults aged 65 and older, preferences for obesity medicines, and experiences with pills and injections.
The CagriSema data come as the drug remains unapproved for use in the United States. Novo submitted an application for its use in weight management to the U.S. Food and Drug Administration in December 2025 and expects a decision in the fourth quarter of 2026. Chief Executive Mike Doustdar said the company is preparing for a U.S. launch in early 2027, subject to regulatory approval. That means the expected regulatory decision precedes the launch window cited by the company. During ObesityWeek 2026, Novo announced that 26 scientific abstracts from its obesity portfolio would be presented at the conference, held in Washington from November 14 to 17.